Research programme: anti-CD19 antibodies - Bristol-Myers Squibb/Genmab

Drug Profile

Research programme: anti-CD19 antibodies - Bristol-Myers Squibb/Genmab

Latest Information Update: 01 Jul 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Genmab
  • Class Antibodies
  • Mechanism of Action CD19 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies

Most Recent Events

  • 02 Jun 2015 Anti-CD19 antibodies licensed to Genmab
  • 02 Jun 2015 Early research in Haematological malignancies in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top